Home > Insider Trading > Filing (0001012975-15-000238)

Filing Details

Accession Number:: 0001012975-15-000238
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2015-03-19 17:44:55
Reporting Period:: 2015-03-17

Filing Date:: 2015-03-19
Accepted Time:: 2015-03-19 17:44:55
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1586049	Oxford Immunotec Global Plc	OXFD	In Vitro & In Vivo Diagnostic Substances (2835)	000000000

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1249153	Dennis Henner	The John Hancock Tower 200 Clarendon Street, 54Th Floor Boston MA 02116	No	No	Yes	No
1252522	Nicholas Galakatos	The John Hancock Tower 200 Clarendon Street, 54Th Floor Boston MA 02116	No	No	Yes	No
1252523	Robert Liptak	The John Hancock Tower 200 Clarendon Street, 54Th Floor Boston MA 02116	No	No	Yes	No
1252525	Kurt Wheeler	801 Gateway Blvd Ste 410 San Francisco CA 94080	No	No	Yes	No
1431403	Nicholas Simon	101 Main Street Suite 1210 Cambridge MA 02142	No	No	Yes	No
1431441	Clarus Ventures I, Llc	101 Main Street Suite 1210 Cambridge MA 02142	No	No	Yes	No
1431445	Clarus Lifesciences I, L.p.	101 Main Street Suite 1210 Cambridge MA 02142	No	No	Yes	No
1505590	Clarus Ventures I Management, L.p.	C/O Clarus Ventures 101 Main Street, 12Th Floor Cambridge MA 02142	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Ordinary Shares	Disposition	2015-03-17	79,307	$14.67	2,499,755	No	4	S	Direct
Ordinary Shares	Disposition	2015-03-18	25,000	$14.68	2,474,755	No	4	S	Direct
Ordinary Shares	Disposition	2015-03-19	50,012	$14.61	2,424,743	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Footnotes

The price reflected is the weighted-average sale price for shares sold. The range of sale prices for the transactions reported was 14.50 to 14.75 per shares. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
The price reflected is the weighted-average sale price for shares sold. The range of sale prices for the transactions reported was 14.50 to 14.94 per shares. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
The price reflected is the weighted-average sale price for shares sold. The range of sale prices for the transactions reported was 14.50 to 14.93 per shares. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Securities held of record by Clarus Lifesciences I, L.P. ("Clarus"). Clarus Ventures I Management, L.P. (the "GPLP"), as the sole general partner of Clarus, may be deemed to beneficially own certain of the shares held of record by Clarus. Clarus Ventures I, LLC (the "GPLLC"), as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held of record by Clarus. Each of Messrs. Galakatos, Henner, Liptak, Simon and Wheeler, as individual Managing Directors of the GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Each of the GPLP, GPLLC and Messrs. Galakatos, Henner, Liptak, Simon and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which it or he, as applicable, does not have an actual pecuniary interest.